Evotec expands compound management capability to East Coast of the United States

Evotec AG today announced that Evotec (US) Inc. has executed a multi-year lease on a facility specifically designed to expand the offering of its Compound Management Services on the East Coast of the United States. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-expands-compound-management-capability-to-east-coast-of-the-united-states-5129

Weiterlesen

Evotec achieves milestone in drug discovery collaboration with Ono Pharmaceutical Co., Ltd.

Evotec AG today announced that a compound identified and optimised in a research collaboration with Ono Pharmaceutical Co., Ltd. has been nominated to enter pre-clinical development, leading to the payment of an agreed milestone. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-achieves-milestone-in-drug-discovery-collaboration-with-ono-pharmaceutical-co-ltd-5117

Weiterlesen

Evotec expands collaboration with MedImmune, receives milestone payment

Evotec AG today announced that it has expanded the scope of its collaboration with MedImmune, the global biologics arm of AstraZeneca, after hitting a key milestone. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-expands-collaboration-with-medimmune-receives-milestone-payment-5111

Weiterlesen

Evotec acquires Cell Culture Service GmbH

Evotec AG today announced the acquisition of all shares in Cell Culture Service GmbH, a Hamburg-based company which supports the cell culture needs of a world-wide customer base of biotech and Pharmaceutical companies. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-acquires-cell-culture-service-gmbh-5109

Weiterlesen

Evotec and Apeiron Biologics announce collaboration on cancer immunotherapy

Evotec AG today announced that Evotec and Apeiron Biologics have entered into a research collaboration with the objective of developing immunomodulatory lead compounds for the treatment of cancer. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-apeiron-biologics-announce-collaboration-on-cancer-immunotherapy-5107

Weiterlesen